StocksMedium•2 October 2026•
1 min read
Teva and Samsung Bioepis Expand Biosimilar Partnership for Western Markets
Key Facts
1Teva and Samsung Bioepis expanded their partnership to include two new biosimilar candidates, SB41 and SB44.
2Teva will handle the commercialization of the products in the U.S., Europe, and Canada.
Teva Pharmaceutical Industries and Samsung Bioepis expanded their partnership to include two new biosimilar candidates, SB41 and SB44. Korea Biomedical Review reported that Teva will handle the commercialization of these products in the United States, Europe, and Canada, leveraging its existing infrastructure in these key regions.
The expansion aims to combine Samsung Bioepis's development and manufacturing capabilities with Teva's commercial reach in Western markets. The strategic move signals continued growth in the high-demand biosimilars sector.